Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
August 6, 2024

Santen and Cloudbreak enter licence agreement for pterygium treatment

Santen Pharmaceutical has entered into a licensing agreement with Cloudbreak Pharma to develop, manufacture, and commercialise CBT-001, a topical pterygium treatment, for certain territories.

The licensing agreement stipulates that Cloudbreak will receive up to $91m in upfront and milestone payments. Credit: National Cancer Institute on Unsplash.